CARSGEN-B (02171): First patient infusion completed for CT1190B in China Phase I registrational clinical trial

CARSGEN-B (02171) announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its China Phase I registrational clinical trial for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard therapy. The IIT study results of CT1190B were presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress.